{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T07:31:17Z","timestamp":1772177477622,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Geographic differences in disease course and treatment response are well recognized. The purpose of this analysis was to study clinical and histological characteristics, treatment practices and outcome of IgAN cases from a Swiss tertiary center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort analysis identified 158 cases of adult biopsy-proven IgAN by chart review diagnosed between 1980 and 2016. Following detailed phenotyping, standard descriptive methods and univariate analysis were applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The majority of patients was male and of European ancestry. At diagnosis, mean estimated glomerular filtration rate (eGFR) was 55.7 ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      , mean proteinuria was 2.4 g\/d and 69.9% of the patients were hypertensive. Clinical presentation varied according to age. Initial biopsies showed moderate to severe tubular atrophy and interstitial fibrosis (IFTA) in 29.1% and crescents in 36.7% of cases. Therapy included renin-angiotensin-aldosterone-inhibitors in 86.7% as well as immunosuppressive therapy in 46.8% including steroids and other immunosuppressive drugs (28.7%), mainly azathioprin. Outcome included 34.1% complete and 22.2% partial remissions, relapses in 32.0% of patients, while 43.0% of patients progressed to ESKD during follow-up (median 100.0 months). Recurrence rate after transplantation was 18.8%. Immunosuppressive therapy was more frequently used in patients with higher proteinuria level, higher hematuria grade, lower eGFR, more intense IgA and complement C3 staining and crescents. Predictors of progression were higher age, lower eGFR, higher proteinuria and blood pressure as well as crescents and higher extent of IFTA on the initial biopsy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This retrospective cohort analysis gives insight into characteristics and outcome of patients with IgAN from a Swiss tertiary center, treatment practices as well as predictors of outcome and therapy choices. A comparatively high use of immunosuppressive treatment including non-steroid-based regimens was found along with a high rate of progression to ESKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneph.2026.1648950","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:24:47Z","timestamp":1772169887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment practices, characteristics and outcome of immunoglobulin A nephropathy \u2013 a Swiss single center experience"],"prefix":"10.3389","volume":"6","author":[{"given":"Danny Thieny","family":"Taing","sequence":"first","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern","place":["Bern, Switzerland"]},{"name":"Department of Radiation Oncology, Kantonsspital Aarau","place":["Aarau, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern","place":["Bern, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila-Yasmin","family":"Mani","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern","place":["Bern, Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V11101957","article-title":"Intercapillary deposits of igA-igG","volume":"74","author":"Berger","year":"1968","journal-title":"J Urol Nephrol (Paris)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfl342","article-title":"A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study","volume":"21","author":"Wakai","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.50","article-title":"IgA nephropathy","volume":"47","author":"Galla","year":"1995","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.059003823.x","article-title":"What is the difference between IgA nephropathy and Henoch-Sch\u00f6nlein purpura nephritis","volume":"59","author":"Davin","year":"2001","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx189","article-title":"Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey","volume":"33","author":"O\u2019Shaughnessy","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00837.x","article-title":"Epidemiologic data of renal diseases from a single unit in China: analysis based on 13, 519 renal biopsies","volume":"66","author":"Li","year":"2004","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00884-7","article-title":"Is IgA nephropathy the same disease in different parts of the world","volume":"43","author":"Zhang","year":"2021","journal-title":"Semin Immunopathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0002972021","article-title":"The phenotypic difference of IgA nephropathy and its race\/gender-dependent molecular mechanisms","volume":"2","author":"Suzuki","year":"2021","journal-title":"Kidney360"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad199","article-title":"Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis","volume":"16","author":"Lee","year":"2023","journal-title":"Clin Kidney J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1024\/0040-5930\/a000659","article-title":"IgA-Nephropathie und Purpura Sch\u00f6nlein-Henoch \u2013 ein breites Spektrum","volume":"72","author":"Mani","year":"2015","journal-title":"Ther Umsch"},{"key":"B14","first-page":"3","article-title":"Is IgA nephropathy a single disease","volume-title":"Pathogenesis and treatment in IgA nephropathy","author":"Cheung","year":"2015"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad146","article-title":"IgA nephropathy in adults\u2014treatment standard","volume":"38","author":"Gleeson","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw285","article-title":"Pro: STOP immunosuppression in IgA nephropathy","volume":"31","author":"Pozzi","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw286","article-title":"Con: STOP immunosuppression in IgA nephropathy","volume":"31","author":"Rauen","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.09.034","article-title":"Clinical practice patterns in IgA nephropathy: a global questionnaire-based survey","volume":"8","author":"Bansal","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0272-6386(97)90456-x","article-title":"Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases","volume":"29","author":"Haas","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2018.07.021","article-title":"Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN study","volume":"3","author":"Selewski","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12882-018-0829-1","article-title":"Gender-related differences in clinicopathological characteristics and renal outcomes of Chinese patients with IgA nephropathy","volume":"19","author":"Deng","year":"2018","journal-title":"BMC Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.04820511","article-title":"Clinical features and outcomes of IgA nephropathy with nephrotic syndrome","volume":"7","author":"Kim","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"sfad230","DOI":"10.1093\/ckj\/sfae230","article-title":"Long-term outcomes of patients with IgA nephropathy in the German CKD cohort","volume":"17","author":"Stamellou","year":"2024","journal-title":"Clin Kidney J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2010010117","article-title":"Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy","volume":"21","author":"Pozzi","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy302","article-title":"Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update","volume":"35","author":"Coppo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12882-025-03958-y","article-title":"Lifetime progression of IgA nephropathy: a retrospective cohort study with extended long-term follow-up","volume":"26","author":"Rivedal","year":"2025","journal-title":"BMC Nephrol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/ckj\/sfaa029","article-title":"Spatiotemporal trends and prognosis of end-stage renal disease patients with biopsy-proven immunoglobulin A nephropathy in France from 2010 to 2014","volume":"14","author":"Robert","year":"2020","journal-title":"Clin Kidney J"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1681\/asn.0000000551","article-title":"From despair to promise: the dawn of novel treatment in IgA nephropathy","volume":"36","author":"Tang","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"B36","article-title":"IgA-Nephropathie - Die Berner Erfahrung - Retrospektive Analyse klinischer Daten von Patienten der Universit\u00e4tsklinik f\u00fcr Nephrologie und Hypertonie des Inselspitals","author":"Taing","year":"2020","journal-title":"[master's thesis]"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/2025.06.04.25328997","article-title":"Characteristics and Outcome of Immunoglobulin A Nephropathy \u2013 a Swiss single center experience","author":"Taing","year":"2025","journal-title":"[medRxiv]"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1648950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:24:48Z","timestamp":1772169888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1648950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":37,"alternative-id":["10.3389\/fneph.2026.1648950"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1648950","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1648950"}}